Jeju Startup Unveils AI Drug Management Solution at Japanese Medical Conference

An innovative healthcare startup born in clean Jeju, Indream Healthcare, has successfully debuted on the Japanese stage, signaling its global expansion. They recently unveiled their self-developed artificial intelligence (AI)-based drug management solutions, 'Indream MyChart' and 'Indream Medisupport,' at the 'Asian Congress of Rheumatology 2025' held in Fukuoka, drawing global attention. Kang Byeong-ju, CEO of Indream Healthcare, went beyond merely introducing the solutions. He delivered a lecture on 'How to use AI to optimize your EMR,' vividly sharing real-world application cases of their solutions in managing polypharmacy safety. This clearly demonstrates his deep understanding of the medical field and his capacity for technological convergence, as a practicing rheumatologist and an associate professor at Jeju National University College of Medicine. Indream MyChart leads patient-centered innovation in medication management. It easily and automatically collects and organizes medication information for patients with just self-authentication, providing extensive international-level safety data – such as drug interactions, safety ratings during pregnancy/lactation, caution drugs for the elderly, common side effects, and QT prolongation risk – in a way that patients can intuitively understand. This greatly helps patients clearly understand and manage their own medication information. For medical professionals, 'Indream Medisupport' is organically linked with MyChart, analyzing and warning of potential risk signals in real-time during the prescription process. It is an essential tool that helps medical professionals make safer and more precise prescription decisions by identifying potential risk factors in advance within complex polypharmacy prescription environments. Medisupport has already been actively utilized in actual clinical practice at Jeju National University Hospital since last year, proving its efficacy, and its adoption by Ilsan CHA Hospital has also been confirmed, signaling nationwide expansion. CEO Kang Byeong-ju emphasized, "The MyChart-Medisupport integrated ecosystem is the core of precision medicine, maximizing the safety and efficiency of complex polypharmacy prescriptions." He further expressed his ambition, saying, "With this international conference presentation as a turning point, Indream Healthcare will fully embark on its global market entry as an internationally verified medical AI solution." Discovered in 2023 through the Jeju Creative Economy Innovation Center's accelerating program, Indream Healthcare is garnering expectations as a key player to lead the future of K-Healthcare, based on CEO Kang's expertise and innovative technology.